Boston Scientific and Biophan Expand R&D Relationship

Boston Scientific and Biophan Expand R&D Relationship
Companies to Extend Joint Development Program to Multiple Products 


ROCHESTER, N.Y., June 1  /PRNewswire-FirstCall/ -- Biophan Technologies, Inc.
(OTC:BIPH) (BULLETIN BOARD: BIPH) , a leading developer of next generation
biomedical technology, announced today that it has completed Phase I of a
three-part joint development program with Boston Scientific (NYSE:BSX), a
medical device company with a $32 billion capitalization.  Sales for Boston
Scientific reached $3.75 billion over the last year and are on a run rate of
over $5 billion for 2005.  The program involves exploring the use of Biophan's
cutting-edge, MRI safe and image compatible technologies with a variety of
Boston Scientific products.

The companies have already begun the next two phases, in which Biophan will
receive additional payments and will extend Boston Scientific's first right to
negotiate the licensing of Biophan technologies that result from the companies'
joint development efforts.  In addition, the companies are exploring ways to
further expand their relationship by providing access to Biophan's technologies
for additional products.

"We are extremely pleased to be aligned with a company the size of, and with
the marketing strength of Boston Scientific," stated Michael Weiner, CEO of
Biophan.  "Not only have we received funding contributing to evaluating our
technologies, we also have been able to interact with one of the most
innovative and forward thinking companies in the medical device sector.  The
access to Boston Scientific personnel has significantly helped us hone our
solutions to meet the needs of the medical device industry, including
identifying new applications that can benefit from MRI safety and image
compatibility."

About Biophan Technologies

Biophan Technologies develops and markets cutting-edge technologies designed to
make biomedical devices -- such as cardiac pacemakers, surgical and diagnostic
tools -- safe and compatible with magnetic resonance imaging (MRI) equipment. 
The Company develops enabling technologies for implanted medical systems such
as pacemakers, and interventional surgical devices such as catheters and
guidewires, as well as stents and other implants that can be safely and
effectively imaged under MRI.  The technology is also being used to create
enhanced MRI contrast agents.  Committed to growth through innovation and
developmental leadership, Biophan and its licensors have nine issued U.S.
patents and over fifty patents pending, in areas including nanotechnology
(nanomagnetic particle coatings), radio frequency filters, polymer composites,
and photonics.  Biophan's technology will help realize its goal of one day
making all biomedical devices capable of safely and successfully working with
MRI.  For more information, please visit http://www.biophan.com/.

About Boston Scientific Corporation

Boston Scientific is a worldwide developer, manufacturer, and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties.  For more information, please visit:
http://www.bostonscientific.com/.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-
looking statements.  Actual results could differ materially from such
statements expressed or implied herein as a result of a variety of factors
including, but not limited to: the development of Biophan's MRI technologies;
the approval of Biophan's patent applications; the successful implementation of
Biophan's research and development programs; the acceptance by the market of
Biophan's products; competition and the timing of projects and trends in future
operating performance, as well as other factors expressed from time to time in
Biophan's periodic filings with the Securities and Exchange Commission (the
"SEC").  As a result, this press release should be read in conjunction with
Biophan's periodic filings with the SEC.  The forward-looking statements
contained herein are made only as of the date of this press release, and
Biophan undertakes no obligation to publicly update such forward-looking
statements to reflect subsequent events or circumstances. 

DATASOURCE: Biophan Technologies, Inc.



CONTACT:  Carolyn Hotchkiss of Biophan Technologies, Inc.,

[phone]; Press Interviews: Michael Weiner, [phone]



Web site:  http://www.biophan.com/

http://www.bostonscientific.com/ 

Copyright